硫化砷(III)

硫化砷(III)用途

【用途一】
钛镍黄的耐候性及耐久性胜过金红石型钛白，可用于卷钢涂料、汽车涂料、车辆和航空涂料，亦用于标牌、路标用的涂料和塑料等。用于钛镍黄优异的稳定性，可用于在高温下应用的耐高温涂料，在高温下注塑的塑料和其它耐热涂料。钛镍黄化学稳定性好，可用于化工厂的设备和墙壁涂料、水泥涂料、乳胶涂料和酸固化氨基树脂涂料。钛镍黄无毒，可在玩具涂料和玩具塑料、食品包装塑料和食品罐的印刷油墨等方面应用。钛镍黄的主要缺点是色浅，着色力低，粒度远较钛白粉为粗，分散性差，不宜单独作为黄色颜料，多用于作为黄基和其它有机黄色颜料配合使用，用于浅色耐候性外用涂料。
【用途二】
同“雄黄”。

硫化砷(III)名称

[ CAS 号 ]:
1303-33-9

[ 中文名 ]:
硫化砷(III)

[ 英文名 ]:
Arsenic(III) sulfide

[英文别名 ]:

MFCD00003435
EINECS 215-117-4

硫化砷(III)物理化学性质

[ 密度 ]:
3.43 g/mL at 25ºC(lit.)

[ 沸点 ]:
707ºC

[ 熔点 ]:
300ºC(lit.)

[ 分子式 ]:
As₂H₂S₃

[ 分子量 ]:
248.05400

[ 闪点 ]:
707°C

[ 精确质量 ]:
247.77500

[ PSA ]:
89.48000

[ LogP ]:
1.40800

[ 外观性状 ]:
黄色至橙色粉末

[ 储存条件 ]:
通风低温干燥,与库房食品原料和酸分开存放

[ 水溶解性 ]:
每100毫升水中的溶解克数: 4.454×10-4/20℃

硫化砷(III)MSDS

详细MSDS(安全技术说明书)

硫化砷(III)毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: CG2638000

CHEMICAL NAME :: Arsenic sulfide (As2S3)

CAS REGISTRY NUMBER :: 1303-33-9

LAST UPDATED :: 199712

DATA ITEMS CITED :: 33

MOLECULAR FORMULA :: As2-S3

MOLECULAR WEIGHT :: 246.02

WISWESSER LINE NOTATION :: .AS2.S3

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 185 mg/kg

TOXIC EFFECTS :: Behavioral - muscle weakness Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

REFERENCE :: GTPZAB Gigiena Truda i Professional'nye Zabolevaniya. Labor Hygiene and Occupational Diseases. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.1-36, 1957-1992. For publisher information, see MTPEEI Volume(issue)/page/year: 28(7),53,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Administration onto the skin

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 936 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: GTPZAB Gigiena Truda i Professional'nye Zabolevaniya. Labor Hygiene and Occupational Diseases. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.1-36, 1957-1992. For publisher information, see MTPEEI Volume(issue)/page/year: 28(7),53,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 254 mg/kg

TOXIC EFFECTS :: Behavioral - muscle weakness Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

REFERENCE :: GTPZAB Gigiena Truda i Professional'nye Zabolevaniya. Labor Hygiene and Occupational Diseases. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.1-36, 1957-1992. For publisher information, see MTPEEI Volume(issue)/page/year: 28(7),53,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 215 mg/kg

TOXIC EFFECTS :: Behavioral - muscle weakness Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

REFERENCE :: GTPZAB Gigiena Truda i Professional'nye Zabolevaniya. Labor Hygiene and Occupational Diseases. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.1-36, 1957-1992. For publisher information, see MTPEEI Volume(issue)/page/year: 28(7),53,1984 ** TUMORIGENIC DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 125 mg/kg

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - tumors at site of application

REFERENCE :: BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- Volume(issue)/page/year: 20,190,1966

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intratracheal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 73885 ug/kg/15W-C

REFERENCE :: CALEDQ Cancer Letters (Shannon, Ireland). (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1975- Volume(issue)/page/year: 27,99,1985 *** REVIEWS *** ACGIH TLV-TWA 0.01 mg(As)/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 ACGIH TLV-Confirmed human carcinogen DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 IARC Cancer Review:Human Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 23,39,1980 *** U.S. STANDARDS AND REGULATIONS *** MSHA STANDARD-air:TWA 0.5 mg(As)/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: 3,16,1971 OSHA-cancer hazard CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1910.1018,1987 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-ARAB Republic of Egypt:TWA 0.2 mg(As)/m3 JAN 1993 OEL-AUSTRALIA:TWA 0.05 mg(As)/m3;Carcinogen JAN 1993 OEL-BELGIUM:TWA 0.2 mg(As)/m3 JAN 1993 OEL-DENMARK:TWA 0.05 mg(As)/m3 JAN 1993 OEL-FINLAND;Carcinogen JAN 1993 OEL-FRANCE:TWA 0.2 mg(As)/m3 JAN 1993 OEL-HUNGARY:STEL 0.5 mg(As)/m3;Carcinogen JAN 1993 OEL-INDIA:TWA 0.2 mg(As)/m3 JAN 1993 OEL-THE PHILIPPINES:TWA 0.5 mg(As)/m3 JAN 1993 OEL-POLAND:TWA 0.3 mg(As)/m3 JAN 1993 OEL-SWEDEN:TWA 0.03 mg(As)/m3;Carcinogen JAN 1993 OEL-SWITZERLAND:TWA 0.1 mg(As)/m3;Carcinogen JAN 1993 OEL-THAILAND:TWA 0.5 mg(As)/m3 JAN 1993 OEL-TURKEY:TWA 0.5 mg(As)/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 0.2 mg(As)/m3 JAN 1993 OEL IN BULGARIA, COLOMBIA, JORDAN, KOREA check ACGIH TLV OEL IN NEW ZEALAND, SINGAPORE, VIETNAM check ACGIH TLV *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO ARSENIC, INORGANIC-air:CA CL 0.002 mg(As)/m3/15M REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992 NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - M1486 No. of Facilities: 46 (estimated) No. of Industries: 2 No. of Occupations: 3 No. of Employees: 123 (estimated)

硫化砷(III)安全信息

[ 符号 ]:

GHS06, GHS09

[ 信号词 ]:
Danger

[ 危害声明 ]:
H301 + H311 + H331-H410

[ 警示性声明 ]:
P261-P273-P280-P301 + P310-P311-P501

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
T:Toxic; N:Dangerous for the Environment;

[ 风险声明 (欧洲) ]:
R23/25;R50/53

[ 安全声明 (欧洲) ]:
S1/2-S20/21-S28-S45-S60-S61

[ 危险品运输编码 ]:
UN 1557 6.1/PG 2

[ WGK德国 ]:
3

[ RTECS号 ]:
CG2638000

[ 包装等级 ]:
III

[ 危险类别 ]:
6.1

硫化砷(III)制备

1.将硫酸法钛白生产中的水合二氧化钛充分洗涤后，送入打浆罐中，并按一定比例加入具有足够活性的含镍和锑的化合物，以及可促进煅烧时晶型转化的处理剂后，按一定浓度混合均匀，经过滤后，将滤饼送入回转窑，在1000℃左右的温度下煅烧完全晶格转化。煅烧温度过高，会发生物料烧结而影响成品性能。故可根据不同用途作不同处理。

2.先将As2O3溶于稀盐酸(1∶4)中(最好是先溶于氢氧化钠后，再加入盐酸，使pH值在2以下)，然后将硫化氢通入溶液，使As2S3沉淀出来。

硫化砷(III)文献

Arsenic sulfide, the main component of realgar, a traditional Chinese medicine, induces apoptosis of gastric cancer cells in vitro and in vivo.

Drug Des. Devel. Ther. 9 , 79-92, (2015)

Arsenic sulfide (As4S4), the main component of realgar, a traditional Chinese medicine, has shown antitumor efficacy in several tumor types, especially for acute promyelocytic leukemia. In this study,...

As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.

Proc. Natl. Acad. Sci. U. S. A. 107(50) , 21683-8, (2010)

Arsenic, a curative agent for acute promyelocytic leukemia, induces cell apoptosis and degradation of BCR-ABL in chronic myelogenous leukemia (CML). We demonstrated that ubiquitination and degradation...

A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia.

Proc. Natl. Acad. Sci. U. S. A. 106(9) , 3378-83, (2009)

In this study, we show that combined use of Imatinib (IM) and arsenic sulfide [As(4)S(4) (AS)] exerts more profound therapeutic effects in a BCR/ABL-positive mouse model of chronic myeloid leukemia (C...

更多文献